Quantcast

Latest Alzheimer's Stories

2014-06-04 04:21:45

VIENNA, June 4, 2014 /PRNewswire/ -- AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients. Upon treatment with AD04, effects consistent with disease modification were achieved for at least 18 months in 47% of treated patients. This beneficial effect was dose dependent and more effective in...

2014-06-02 12:29:55

Alzheimer's Association® Invites Everyone to Go Purple to Raise Awareness of Alzheimer's Disease and Brain Risk CHICAGO, June 2, 2014 /PRNewswire-USNewswire/ -- There are at least 44 million people worldwide living with Alzheimer's disease and other dementias, and those numbers are expected to grow to 76 million by 2030. During the inaugural Alzheimer's & Brain Awareness Month this June, the Alzheimer's Association(®) is asking people around the world to wear purple - the color of the...

2014-05-21 16:27:02

PITTSBURGH, May 21, 2014 /PRNewswire/ -- Cognition Therapeutics Inc. (CogRx), an innovative research and drug discovery organization focused on the development of novel disease-modifying therapeutics for neurodegenerative diseases, announced today that its small molecule soluble Abeta receptor antagonist program for the treatment of Alzheimer's disease (AD) has been selected for funding by the National Institute on Aging (NIA)/NIH Alzheimer's Disease Drug Development Program (U01)....

2014-05-05 12:29:07

"Until there is a cure, we must care for the carer." OMAHA, Neb., May 5, 2014 /PRNewswire/ -- As the world population ages, diseases such as Alzheimer's become more prevalent. And with a surplus of people who need care, there is often a shortage of those who are able and willing to give care. Paul Hogan, chairman and co-founder of Home Instead Senior Care®, addressed ways to support caregivers at the 29(th) Alzheimer's Disease International Conference....

2014-05-02 12:27:14

Drug Could Be the First to Slow the Progression of Alzheimer's Disease NEW YORK, May 2, 2014 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it raised more than $1.1 million in support of a clinical trial to test an existing drug for the treatment of Alzheimer's disease. The $1.1 million was generated during the "Fund a Scientist" auction at its Eighth Annual Connoisseur's Dinner on May 1, 2014, and awarded to Jeffrey Cummings, MD,...

2014-05-01 16:30:38

George Vradenburg Appointed to Council WASHINGTON, May 1, 2014 /PRNewswire-USNewswire/ -- The World Dementia Council, meeting for the first time in London, England on Wednesday, agreed to priorities for the upcoming year and to mobilizing a worldwide effort to find a cure for Alzheimer's and dementia. Supported by the UK Government, and an outgrowth of the 2013 G8 Dementia Summit, the World Dementia Council was created to champion innovation in dementia across diagnosis, treatment, and care...

2014-04-23 08:32:54

Resource Will Provide Comprehensive Overview of the Science for Prevention Therapies NEW YORK, April 23, 2014 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today the launch of Cognitive Vitality, a new online resource developed to provide a comprehensive and credible overview and analysis of the science for specific strategies to prevent Alzheimer's and related dementias. The resource showcases the strength of the science for and against...

2014-04-22 08:30:14

--Research Published in the Journal of Molecular Biology-- CAMBRIDGE, Mass., April 22, 2014 /PRNewswire/ -- Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases. These molecules are based on what the Company calls a general amyloid interaction motif, or GAIM, which recognizes a...

2014-04-14 12:32:55

Researchers recruiting patients with mild to moderate Alzheimer's disease to participate in six week study SUN CITY, Ariz., April 14, 2014 /PRNewswire/ -- Banner Sun Health Research Institute is proud to announce it is one of just five facilities in the United States to launch a new clinical trial for patients with mild to moderate Alzheimer's disease (AD). This study, titled "Effect of NeuroAD(TM), Combined TMS Stimulation and Cognitive Training, on the cognitive function of mild to...

2014-04-04 12:28:09

WASHINGTON, April 4, 2014 /PRNewswire-USNewswire/ -- The pain and helplessness of those suffering from the ravages of Alzheimer's disease (AD)--a fatal, degenerative condition for which there is currently no cure nor any effective treatment-- is the basis for a bipartisan bill unveiled in the House of Representatives today by U.S. Reps. Chris Smith (R-NJ) and Chaka Fattah (D-PA). The bill, HRes. 489, calls on the U.S. to both engage in and lead a coordinated, international effort to advance...


Word of the Day
ween
  • To think; to imagine; to fancy.
  • To be of opinion; have the notion; think; imagine; suppose.
The word 'ween' comes from Middle English wene, from Old English wēn, wēna ("hope, weening, expectation"), from Proto-Germanic *wēniz, *wēnōn (“hope, expectation”), from Proto-Indo-European *wen- (“to strive, love, want, reach, win”).
Related